313 related articles for article (PubMed ID: 26752541)
1. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
[TBL] [Abstract][Full Text] [Related]
2. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials.
Liao X; Qiu S; Bao Y; Wang W; Yang L; Wei Q
World J Urol; 2019 Jun; 37(6):1061-1074. PubMed ID: 30523399
[TBL] [Abstract][Full Text] [Related]
5. Avanafil - a further step to tailoring patient needs and expectations.
Boeri L; Capogrosso P; Ventimiglia E; Serino A; La Croce G; Russo A; Damiano R; Montorsi F; Salonia A
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1171-81. PubMed ID: 27232892
[TBL] [Abstract][Full Text] [Related]
6. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.
Bruzziches R; Francomano D; Gareri P; Lenzi A; Aversa A
Expert Opin Pharmacother; 2013 Jul; 14(10):1333-44. PubMed ID: 23675780
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterases 5 Inhibitors and Erectile Dysfunction Recovery after Pelvic Surgery: Future Perspectives for New Drugs and New Formulations.
Lombardo R; Tema G; De Nunzio C
Curr Drug Targets; 2021; 22(1):31-37. PubMed ID: 32981502
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.
Hong JH; Kwon YS; Kim IY
Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):183-192. PubMed ID: 27690667
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.
Zhao C; Kim SW; Yang DY; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Moon KH; Chung WS; Min KS; Suh JK; Hyun JS; Park K; Park JK
BJU Int; 2012 Dec; 110(11):1801-6. PubMed ID: 22448738
[TBL] [Abstract][Full Text] [Related]
10. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Hsu JC; Tang DH; Lu CY
Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebo-controlled trial.
Schneider T; Gleissner J; Merfort F; Hermanns M; Beneke M; Ulbrich E
J Sex Med; 2011 Oct; 8(10):2904-11. PubMed ID: 21771281
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis.
Madeira CR; Tonin FS; Fachi MM; Borba HH; Ferreira VL; Leonart LP; Bonetti AF; Moritz RP; Trindade ACLB; Gonçalves AG; Fernandez-Llimos F; Pontarolo R
World J Urol; 2021 Mar; 39(3):953-962. PubMed ID: 32388784
[TBL] [Abstract][Full Text] [Related]
13. An update on the drug safety of treating erectile dysfunction.
Gul M; Serefoglu EC
Expert Opin Drug Saf; 2019 Oct; 18(10):965-975. PubMed ID: 31433252
[No Abstract] [Full Text] [Related]
14. The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis.
Corona G; Rastrelli G; Burri A; Jannini EA; Maggi M
Expert Opin Drug Saf; 2016; 15(2):237-47. PubMed ID: 26646748
[TBL] [Abstract][Full Text] [Related]
15. Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.
Porst H; Hell-Momeni K; Büttner H
Expert Opin Pharmacother; 2012 Jul; 13(10):1481-94. PubMed ID: 22725705
[TBL] [Abstract][Full Text] [Related]
16. [Phosphodesterase type 5 inhibitors clinical efficiency and role in therapy for erectile dysfunction].
Shodmonova ZR; Gafarov RR; Allazov SA; Giyasov SI
Urologiia; 2021 May; (2):135-140. PubMed ID: 33960173
[TBL] [Abstract][Full Text] [Related]
17. How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors.
Jannini EA; DeRogatis LR; Chung E; Brock GB
J Sex Med; 2012 Jan; 9(1):26-33. PubMed ID: 22221307
[TBL] [Abstract][Full Text] [Related]
18. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
19. Advances in pharmacotherapy for erectile dysfunction and associated cardiac impact.
Voznesensky I; DeLay KJ; Hellstrom WJ
Expert Opin Pharmacother; 2016 Dec; 17(17):2281-2289. PubMed ID: 27677349
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction.
Paick JS; Ahn TY; Choi HK; Chung WS; Kim JJ; Kim SC; Kim SW; Lee SW; Min KS; Moon KH; Park JK; Park K; Park NC; Suh JK; Yang DY; Jung HG
J Sex Med; 2008 Nov; 5(11):2672-80. PubMed ID: 18638004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
